Clinical trials: Undefined
Graft-Versus-Host Disease, GVHD
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
- Conditions
- Graft-Versus-Host Disease, GVHD, Undefined
- Trial name
- NCT05675930
- Testing
- Photobiomodulation Therapy
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Core Disease, Centronuclear Myopathy
Molecular and Genetic Studies of Congenital Myopathies
In the Congenital Myopathy Research Program at Boston Children's Hospital and Harvard Medical School, the researchers are studying the congenital myopathies (neuromuscular diseases present from birth), including central core…
- Conditions
- Central Core Disease, Centronuclear Myopathy, Congenital Fiber Type Disproportion, Multiminicore Disease
- Trial name
- NCT00272883
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Boston Children's Hospital
Undefined
CSAPG Early Warning Score
The Early Warning Score (EWS) has been shown in previous studies to be correlated with mortality and mean hospital stay, but it is unknown whether the implementation of the scale improves mortality and mean hospital stay.
- Trial name
- CEWS (NCT04905095)
- Testing
- EWS, usual clinical care
- Where
- Spain
- Volunteers
- 15,998 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Severe Combined Immunodeficiency Disease, Severe Primary Immunodeficiency Disorder
Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
This study is to discover whether children with severe combined immunodeficiency disease (SCID) or other primary immunodeficiency disorder (PID) for which no satisfactory treatment other than stem cell transplantation (SCT)…
- Conditions
- Severe Combined Immunodeficiency Disease, Severe Primary Immunodeficiency Disorder, Undefined T Cell Deficiency Disorder, Wiskott-Aldrick Syndrome
- Trial name
- MASCI (NCT00579137)
- Testing
- Campath -1H, Fludarabine, Anti-CD45
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine